LGALS1 and central nervous system cancer: CS nanocapsules were delivered intranasally for RNA interference (RNAi) mediated knockdown of galectin-1 in GL261 mouse glioma line, and demonstrated successful nose-to-brain transport of siRNA along with survival benefits when delivered with programmed cell death-1 (PD-1) immunotherapy in vivo (61).